{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:02:32Z","timestamp":1791237752713,"version":"4.1.0"},"reference-count":94,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T00:00:00Z","timestamp":1733702400000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010414","name":"Health Research Board","doi-asserted-by":"publisher","award":["SPHeRE\/2013\/1"],"award-info":[{"award-number":["SPHeRE\/2013\/1"]}],"id":[{"id":"10.13039\/100010414","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Postdoctoral Researcher","award":["ILP-HSR-2019-011"],"award-info":[{"award-number":["ILP-HSR-2019-011"]}]},{"name":"Irish Research Council Government of Ireland Postdoctoral Fellowship Award","award":["GOIPD\/2023\/1168"],"award-info":[{"award-number":["GOIPD\/2023\/1168"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Patient and public involvement is increasingly advocated in health policy, research and practice. Patients and people with lived experience, carers and the general public should have a say in how policy is generated, how services are delivered and how research is conducted. Through this perspective article, we hope to stimulate discussion and debate around industry influence in patient and public involvement, specifically pertaining to patient organizations, which often play a key role in patient and public involvement activities. As momentum gathers around patient and public involvement in many countries, it is timely to discuss the nature and extent of commercial influences in such activities, the (un)anticipated consequences of industry\u2013patient interactions, including conflicts of interest and motivated bias, and how we might better manage, or negate, such interactions. Patient and public involvement must be integral to research, policy and practice. While further research is needed to examine the interactions, and consequences of pharmaceutical industry interactions with patients, several practical steps can be taken in the interim. Structures, processes and supports, which are fit for purpose, are needed to ensure independence, power and legitimacy within patient and public involvement activities, and that patient advocates have their voices heard, and ultimately acted upon.<\/jats:p>","DOI":"10.1093\/heapro\/daae188","type":"journal-article","created":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T23:38:47Z","timestamp":1733873927000},"source":"Crossref","is-referenced-by-count":4,"title":["Commercial influences on patient and public involvement: a renewed call for research and action"],"prefix":"10.1093","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7742-8118","authenticated-orcid":false,"given":"Marita","family":"Hennessy","sequence":"first","affiliation":[{"name":"College of Medicine and Health, University College Cork , Cork ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Fahey","sequence":"additional","affiliation":[{"name":"Department of General Practice, RCSI University of Medicine and Health Sciences , Dublin ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Larkin","sequence":"additional","affiliation":[{"name":"Department of General Practice, RCSI University of Medicine and Health Sciences , Dublin ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,12,9]]},"reference":[{"key":"2024121023383873000_CIT0001","doi-asserted-by":"crossref","first-page":"dyae023","DOI":"10.1093\/ije\/dyae023","article-title":"Moral jeopardy, conflicts of interest and the integrity of public health research","volume":"53","author":"Adams","year":"2024","journal-title":"International Journal of Epidemiology"},{"key":"2024121023383873000_CIT0002","author":"American Medical Association","year":"2020"},{"key":"2024121023383873000_CIT0003","article-title":"ABPI code of practice for the pharmaceutical industry 2024","author":"Association of the British Pharmaceutical Industry","year":"2024"},{"key":"2024121023383873000_CIT0004","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1369-7625.2007.00472.x","article-title":"Health consumer and patients\u2019 organizations in Europe: towards a comparative analysis","volume":"11","author":"Baggott","year":"2008","journal-title":"Health Expectations"},{"key":"2024121023383873000_CIT0005","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.socscimed.2014.07.016","article-title":"The voluntary sector and health policy: the role of national level health consumer and patients\u2019 organisations in the UK","volume":"123","author":"Baggott","year":"2014","journal-title":"Social Science & Medicine (1982)"},{"key":"2024121023383873000_CIT0006","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s11673-018-9859-4","article-title":"Representing whom? U.K. health consumer and patients\u2019 organizations in the policy process","volume":"15","author":"Baggott","year":"2018","journal-title":"Journal of Bioethical Inquiry"},{"key":"2024121023383873000_CIT0007","doi-asserted-by":"crossref","first-page":"52","DOI":"10.12927\/hcpap.2023.26995","article-title":"Competing values, competing claims: diversity among patient advocates who intervene to shape policies on drugs for rare diseases","volume":"21","author":"Batt","year":"2023","journal-title":"Healthcare Papers"},{"key":"2024121023383873000_CIT0008","doi-asserted-by":"crossref","DOI":"10.59962\/9780774833868","volume-title":"Health Advocacy, Inc.: How Pharmaceutical Funding Changed the Breast Cancer Movement","author":"Batt","year":"2017"},{"key":"2024121023383873000_CIT0009","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11673-019-09956-8","article-title":"Pharmaceutical ethics and grassroots activism in the United States: a social history perspective","volume":"17","author":"Batt","year":"2020","journal-title":"Journal of Bioethical Inquiry"},{"key":"2024121023383873000_CIT0010","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/hsc.13111","article-title":"Attitudes and approaches to patient and public involvement across Europe: a systematic review","volume":"29","author":"Biddle","year":"2021","journal-title":"Health and Social Care in the Community"},{"key":"2024121023383873000_CIT0011","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2307\/3857339","article-title":"Fiduciary duties and the shareholder-management relation: or, what\u2019s so special about shareholders","volume":"4","author":"Boatright","year":"1994","journal-title":"Business Ethics Quarterly"},{"key":"2024121023383873000_CIT0012","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1515\/scr-2015-0002","article-title":"From medicalisation to pharmaceuticalisation\u2014a sociological overview. New scenarios for the sociology of health","volume":"12","author":"Bordogna","year":"2014","journal-title":"Social Change Review"},{"key":"2024121023383873000_CIT0013","author":"Boseley","year":"2006"},{"key":"2024121023383873000_CIT0014","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1136\/bmj.p1658","article-title":"Medical royal colleges receive millions from drug and medical devices companies","volume":"382","author":"Boytchev","year":"2023","journal-title":"BMJ"},{"key":"2024121023383873000_CIT0015","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/j.1369-7625.2012.00795.x","article-title":"Mapping the impact of patient and public involvement on health and social care research: a systematic review","volume":"17","author":"Brett","year":"2014","journal-title":"Health Expectations"},{"key":"2024121023383873000_CIT0016","doi-asserted-by":"crossref","first-page":"l129","DOI":"10.1136\/bmj.l129","article-title":"Patient organizations and conflict of interest","volume":"364","author":"Bruno","year":"2019","journal-title":"BMJ"},{"key":"2024121023383873000_CIT0017","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1136\/bmj.331.7529.1359-b","article-title":"Drug companies told that sponsoring patients\u2019 groups might help win approval for their products","volume":"331","author":"Burton","year":"2005","journal-title":"BMJ"},{"key":"2024121023383873000_CIT0018","author":"Butler","year":"2020"},{"key":"2024121023383873000_CIT0019","author":"Centers for Medicare & Medicaid Services","year":"2024","journal-title":"What is Open Payments?"},{"key":"2024121023383873000_CIT0020","author":"Colombo","year":"2020"},{"key":"2024121023383873000_CIT0021","doi-asserted-by":"crossref","first-page":"e34974","DOI":"10.1371\/journal.pone.0034974","article-title":"Patient organizations\u2019 funding from pharmaceutical companies: is disclosure clear, complete and accessible to the public? An Italian survey","volume":"7","author":"Colombo","year":"2012","journal-title":"PLoS One"},{"key":"2024121023383873000_CIT0022","volume-title":"Branding the Cure: A Consumer Perspective on Corporate Social Responsibility, Drug Promotion and the Pharmaceutical Industry in Europe","author":"Consumers International","year":"2006"},{"key":"2024121023383873000_CIT0023","doi-asserted-by":"crossref","first-page":"e025166","DOI":"10.1136\/bmjopen-2018-025166","article-title":"Patient, client, consumer, survivor or other alternatives? A scoping review of preferred terms for labelling individuals who access healthcare across settings","volume":"9","author":"Costa","year":"2019","journal-title":"BMJ Open"},{"key":"2024121023383873000_CIT0024","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1001\/jamainternmed.2016.2765","article-title":"Pharmaceutical industry\u2013sponsored meals and physician prescribing patterns for medicare beneficiaries","volume":"176","author":"DeJong","year":"2016","journal-title":"JAMA Internal Medicine"},{"key":"2024121023383873000_CIT0025","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/1472-6963-14-89","article-title":"Patient engagement in research: a systematic review","volume":"14","author":"Domecq","year":"2014","journal-title":"BMC Health Services Research"},{"key":"2024121023383873000_CIT0026","author":"EFPIA","year":"2020"},{"key":"2024121023383873000_CIT0027","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1192\/bjp.bp.112.119818","article-title":"Impact of patient involvement in mental health research: longitudinal study","volume":"203","author":"Ennis","year":"2013","journal-title":"The British Journal of Psychiatry"},{"key":"2024121023383873000_CIT0028","author":"EUPATI","year":"2024"},{"key":"2024121023383873000_CIT0029","author":"European Patients Forum","year":"2022"},{"key":"2024121023383873000_CIT0030","doi-asserted-by":"crossref","first-page":"e011124","DOI":"10.1136\/bmjopen-2016-011124","article-title":"Conflict of interest between professional medical societies and industry: a cross-sectional study of Italian medical societies\u2019 websites","volume":"6","author":"Fabbri","year":"2016","journal-title":"BMJ Open"},{"key":"2024121023383873000_CIT0031","doi-asserted-by":"crossref","first-page":"l6925","DOI":"10.1136\/bmj.l6925","article-title":"Industry funding of patient and health consumer organisations: systematic review with meta-analysis","volume":"368","author":"Fabbri","year":"2020","journal-title":"BMJ"},{"key":"2024121023383873000_CIT0032","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1177\/0020731418823376","article-title":"Pharmaceutical industry funding of health consumer groups in Australia: a cross-sectional analysis","volume":"49","author":"Fabbri","year":"2019","journal-title":"International Journal of Health Services: Planning, Administration, Evaluation"},{"key":"2024121023383873000_CIT0033","volume-title":"Lethal but Legal: Corporations, Consumption, and Protecting Public Health","author":"Freudenberg","year":"2014"},{"key":"2024121023383873000_CIT0034","doi-asserted-by":"crossref","first-page":"n1273","DOI":"10.1136\/bmj.n1273","article-title":"Industry-funded medical education is always promotion\u2014an essay by Adriane Fugh-Berman","volume":"373","author":"Fugh-Berman","year":"2021","journal-title":"BMJ"},{"key":"2024121023383873000_CIT0035","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1200\/JCO.2020.39.28_suppl.204","article-title":"The benefits and burdens of patient advocacy","volume":"39","author":"Fuld Nasso","year":"2021","journal-title":"Journal of Clinical Oncology"},{"key":"2024121023383873000_CIT0036","doi-asserted-by":"crossref","first-page":"e071138","DOI":"10.1136\/bmjopen-2022-071138","article-title":"Industry funding of patient organisations in the UK: a retrospective study of commercial determinants, funding concentration and disease prevalence","volume":"13","author":"Gentilini","year":"2023","journal-title":"BMJ Open"},{"key":"2024121023383873000_CIT0037","doi-asserted-by":"crossref","first-page":"1038409","DOI":"10.3389\/fpubh.2022.1038409","article-title":"The public and patient involvement imperative in Ireland: building on policy drivers","volume":"10","author":"Gilfoyle","year":"2022","journal-title":"Frontiers in Public Health"},{"key":"2024121023383873000_CIT0038","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/phe\/phy016","article-title":"The shadows of sunlight: why disclosure should not be a priority in addressing conflicts of interest","volume":"12","author":"Goldberg","year":"2019","journal-title":"Public Health Ethics"},{"key":"2024121023383873000_CIT0039","article-title":"Health Research Board expands opportunity for the public, patients and carers to be involved in health research","author":"Health Research Board","year":"2021"},{"key":"2024121023383873000_CIT0040","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.socscimed.2010.01.005","article-title":"Co-operation between patient organisations and the drug industry in Finland","volume":"70","author":"Hemminki","year":"2010","journal-title":"Social Science & Medicine (1982)"},{"key":"2024121023383873000_CIT0041","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1136\/bmj.326.7400.1208","article-title":"Relationships between the pharmaceutical industry and patients\u2019 organisations","volume":"326","author":"Herxheimer","year":"2003","journal-title":"BMJ"},{"key":"2024121023383873000_CIT0042","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1086\/699713","article-title":"Sex drugs and corporate ventriloquism: how to evaluate science policies intended to manage industry-funded bias","volume":"85","author":"Holman","year":"2018","journal-title":"Philosophy of Science"},{"key":"2024121023383873000_CIT0043","volume-title":"Conflict of Interest in Medical Research, Education, and Practice, The National Academies Collection: Reports funded by National Institutes of Health","author":"Institute of Medicine (US) Committee on Conflict of Interest in Medical Research, Education, and Practice","year":"2009"},{"key":"2024121023383873000_CIT0044","author":"International Alliance of Patients\u2019 Organizations","year":"2023"},{"key":"2024121023383873000_CIT0045","author":"International Alliance of Patients\u2019 Organizations","year":"2023"},{"key":"2024121023383873000_CIT0046","author":"\u00ccPPOSI","year":"2024"},{"key":"2024121023383873000_CIT0047","author":"Irish Pharmaceutical Healthcare Association","year":"2021"},{"key":"2024121023383873000_CIT0048","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1111\/j.1467-9566.2008.01109.x","article-title":"In whose interest? Relationships between health consumer groups and the pharmaceutical industry in the UK","volume":"30","author":"Jones","year":"2008","journal-title":"Sociology of Health & Illness"},{"key":"2024121023383873000_CIT0049","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/hex.13013","article-title":"Financial relationships between patient and consumer representatives and the health industry: a systematic review","volume":"23","author":"Khabsa","year":"2020","journal-title":"Health Expectations"},{"key":"2024121023383873000_CIT0050","doi-asserted-by":"crossref","first-page":"e003850","DOI":"10.1136\/bmjgh-2020-003850","article-title":"Power and the commercial determinants of health: ideas for a research agenda","volume":"6","author":"Lacy-Nichols","year":"2021","journal-title":"BMJ Global Health"},{"key":"2024121023383873000_CIT0051","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1001\/jamainternmed.2021.6045","article-title":"FDA drug approval and the ethics of desperation","volume":"181","author":"Largent","year":"2021","journal-title":"JAMA Internal Medicine"},{"key":"2024121023383873000_CIT0052","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1071\/AH17288","article-title":"How do health consumer organisations in Australia manage pharmaceutical industry sponsorship? A cross-sectional study","volume":"43","author":"Lau","year":"2019","journal-title":"Australian Health Review"},{"key":"2024121023383873000_CIT0053","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1177\/2168479017716715","article-title":"Assessing the financial value of patient engagement: a quantitative approach from CTTI\u2019s patient groups and clinical trials project","volume":"52","author":"Levitan","year":"2018","journal-title":"Therapeutic Innovation & Regulatory Science"},{"key":"2024121023383873000_CIT0054","author":"Lewis","year":"2006"},{"key":"2024121023383873000_CIT0055","doi-asserted-by":"crossref","first-page":"e0212399","DOI":"10.1371\/journal.pone.0212399","article-title":"Association between commercial funding of Canadian patient groups and their views about funding of medicines: an observational study","volume":"14","author":"Lexchin","year":"2019","journal-title":"PLoS One"},{"key":"2024121023383873000_CIT0056","doi-asserted-by":"crossref","first-page":"e055287","DOI":"10.1136\/bmjopen-2021-055287","article-title":"National patient groups in Canada and their disclosure of relationships with pharmaceutical companies: a cross-sectional study","volume":"12","author":"Lexchin","year":"2022","journal-title":"BMJ Open"},{"key":"2024121023383873000_CIT0057","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1007\/s11606-021-06657-0","article-title":"A ray of sunshine: transparency in physician-industry relationships is not enough","volume":"36","author":"Lexchin","year":"2021","journal-title":"Journal of General Internal Medicine"},{"key":"2024121023383873000_CIT0058","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/hex.12519","article-title":"The power of symbolic capital in patient and public involvement in health research","volume":"20","author":"Locock","year":"2017","journal-title":"Health Expectations"},{"key":"2024121023383873000_CIT0059","first-page":"MR000033","article-title":"Industry sponsorship and research outcome","volume":"2","author":"Lundh","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"2024121023383873000_CIT0060","doi-asserted-by":"crossref","first-page":"k5300","DOI":"10.1136\/bmj.k5300","article-title":"Financial interests of patient organisations contributing to technology assessment at England\u2019s National Institute for Health and Care Excellence: policy review","volume":"364","author":"Mandeville","year":"2019","journal-title":"BMJ"},{"key":"2024121023383873000_CIT0061","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11673-020-09982-x","article-title":"Lessons from corporate influence in the opioid epidemic: toward a norm of separation","volume":"17","author":"Marks","year":"2020","journal-title":"Journal of Bioethical Inquiry"},{"key":"2024121023383873000_CIT0062","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1056\/NEJMsr1610625","article-title":"Conflicts of interest for patient-advocacy organizations","volume":"376","author":"McCoy","year":"2017","journal-title":"The New England Journal of Medicine"},{"key":"2024121023383873000_CIT0063","doi-asserted-by":"crossref","first-page":"e078133","DOI":"10.1136\/bmj-2023-078133","article-title":"Raising the bar for disclosure of industry payments to doctors","volume":"384","author":"Menkes","year":"2024","journal-title":"BMJ"},{"key":"2024121023383873000_CIT0064","doi-asserted-by":"crossref","first-page":"e019027","DOI":"10.1136\/bmjopen-2017-019027","article-title":"Does industry-sponsored education foster overdiagnosis and overtreatment of depression, osteoporosis and overactive bladder syndrome? An Australian cohort study","volume":"8","author":"Mintzes","year":"2018","journal-title":"BMJ Open"},{"key":"2024121023383873000_CIT0065","doi-asserted-by":"crossref","first-page":"353","DOI":"10.7326\/M20-5665","article-title":"Are financial payments from the pharmaceutical industry associated with physician prescribing","volume":"174","author":"Mitchell","year":"2021","journal-title":"Annals of Internal Medicine"},{"key":"2024121023383873000_CIT0066","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.healthpol.2021.07.016","article-title":"Payments reported by the pharmaceutical industry in Ireland from 2015 to 2019: an observational study","volume":"125","author":"Moriarty","year":"2021","journal-title":"Health Policy"},{"key":"2024121023383873000_CIT0067","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11673-020-09965-y","article-title":"Commentary: the voice of the people, funded now by your friendly pharmaceutical company","volume":"17","author":"Moynihan","year":"2020","journal-title":"Journal of Bioethical Inquiry"},{"key":"2024121023383873000_CIT0068","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1001\/jamainternmed.2016.9179","article-title":"Toward a healthier patient voice: more independence, less industry funding","volume":"177","author":"Moynihan","year":"2017","journal-title":"JAMA Internal Medicine"},{"key":"2024121023383873000_CIT0069","doi-asserted-by":"crossref","first-page":"e034195","DOI":"10.1136\/bmjopen-2019-034195","article-title":"Mixed methods evaluation of workshops for citizen health advocates about financial conflicts of interests in healthcare","volume":"10","author":"Moynihan","year":"2020","journal-title":"BMJ Open"},{"key":"2024121023383873000_CIT0070","doi-asserted-by":"crossref","first-page":"e0235021","DOI":"10.1371\/journal.pone.0235021","article-title":"Five years of pharmaceutical industry funding of patient organisations in Sweden: cross-sectional study of companies, patient organisations and drugs","volume":"15","author":"Mulinari","year":"2020","journal-title":"PLoS One"},{"key":"2024121023383873000_CIT0071","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s12910-021-00680-w","article-title":"Collective forward-looking responsibility of patient advocacy organizations: conceptual and ethical analysis","volume":"22","author":"M\u00fcller","year":"2021","journal-title":"BMC Medical Ethics"},{"key":"2024121023383873000_CIT0072","author":"NIHR","year":"2021"},{"key":"2024121023383873000_CIT0073","doi-asserted-by":"crossref","first-page":"711","DOI":"10.2190\/HS.37.4.h","article-title":"Corporate colonization of health activism? Irish health advocacy organizations\u2019 modes of engagement with pharmaceutical corporations","volume":"37","author":"O\u2019Donovan","year":"2007","journal-title":"International Journal of Health Services: Planning, Administration, Evaluation"},{"key":"2024121023383873000_CIT0074","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3389\/fsoc.2019.00038","article-title":"A hierarchy of power: the place of patient and public involvement in healthcare service development","volume":"4","author":"O\u2019Shea","year":"2019","journal-title":"Frontiers in Sociology"},{"key":"2024121023383873000_CIT0075","doi-asserted-by":"crossref","first-page":"e037351","DOI":"10.1136\/bmjopen-2020-037351","article-title":"Under-reported relationship: a comparative study of pharmaceutical industry and patient organisation payment disclosures in the UK (2012\u20132016)","volume":"10","author":"Ozieranski","year":"2020","journal-title":"BMJ Open"},{"key":"2024121023383873000_CIT0076","doi-asserted-by":"crossref","first-page":"l1806","DOI":"10.1136\/bmj.l1806","article-title":"Exposing drug industry funding of UK patient organisations","volume":"365","author":"Ozieranski","year":"2019","journal-title":"BMJ"},{"key":"2024121023383873000_CIT0077","doi-asserted-by":"crossref","first-page":"l6694","DOI":"10.1136\/bmj.l6694","article-title":"\u2018Asset exchange\u2019\u2014interactions between patient groups and pharmaceutical industry: Australian qualitative study","volume":"367","author":"Parker","year":"2019","journal-title":"BMJ"},{"key":"2024121023383873000_CIT0078","doi-asserted-by":"crossref","first-page":"e008928","DOI":"10.1136\/bmjopen-2015-008928","article-title":"What do pharmaceutical industry professionals in Europe believe about involving patients and the public in research and development of medicines? A qualitative interview study","volume":"6","author":"Parsons","year":"2016","journal-title":"BMJ Open"},{"key":"2024121023383873000_CIT0079","doi-asserted-by":"crossref","first-page":"p1243","DOI":"10.1136\/bmj.p1243","article-title":"Safeguarding NICE from patient groups\u2019 conflicts of interest","volume":"381","author":"Parvanova","year":"2023","journal-title":"BMJ"},{"key":"2024121023383873000_CIT0080","article-title":"Insulin giant aims to unlock elusive obesity-drug market","author":"Roland","year":"2020","journal-title":"Wall Street Journal"},{"key":"2024121023383873000_CIT0081","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/jlme.12078","article-title":"Patient advocacy organizations: institutional conflicts of interest, trust, and trustworthiness","volume":"41","author":"Rose","year":"2013","journal-title":"The Journal of Law, Medicine & Ethics"},{"key":"2024121023383873000_CIT0082","doi-asserted-by":"crossref","first-page":"e075035","DOI":"10.1136\/bmj-2023-075035","article-title":"Statutory levy on gambling may do more harm than good","volume":"381","author":"van Schalkwyk","year":"2023","journal-title":"BMJ"},{"key":"2024121023383873000_CIT0083","article-title":"As social media \u2018influencers\u2019, patients are getting a voice. And pharma is ready to pay up","author":"Sheridan","year":"2018","journal-title":"STAT"},{"key":"2024121023383873000_CIT0084","volume-title":"The added value of patient organisations","author":"Sienkiewicz","year":"2017"},{"key":"2024121023383873000_CIT0085","doi-asserted-by":"crossref","first-page":"614013","DOI":"10.3389\/frma.2021.614013","article-title":"Epistemic corruption, the pharmaceutical industry, and the body of medical science","volume":"6","author":"Sismondo","year":"2021","journal-title":"Frontiers in Research Metrics and Analytics"},{"key":"2024121023383873000_CIT0086","doi-asserted-by":"crossref","first-page":"100493","DOI":"10.1016\/j.jcpo.2024.100493","article-title":"Pharmaceutical company funding of cancer patient advocacy organizations in the Netherlands","volume":"41","author":"Somers","year":"2024","journal-title":"Journal of Cancer Policy"},{"key":"2024121023383873000_CIT0087","doi-asserted-by":"crossref","first-page":"j1251","DOI":"10.1136\/bmj.j1251","article-title":"Industry links with patient organisations","volume":"356","author":"Taylor","year":"2017","journal-title":"BMJ"},{"key":"2024121023383873000_CIT0088","volume-title":"Feature: Big bucks from big pharma","author":"ThirdSector","year":"2006"},{"key":"2024121023383873000_CIT0089","volume-title":"Looking forward: working with the Medical Research Council towards a public involvement strategy (executive summary)","author":"Vocal, MRC","year":"2023"},{"key":"2024121023383873000_CIT0090","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/j.1467-9566.2011.01320.x","article-title":"The pharmaceuticalisation of society? A framework for analysis","volume":"33","author":"Williams","year":"2011","journal-title":"Sociology of Health & Illness"},{"key":"2024121023383873000_CIT0091","doi-asserted-by":"crossref","first-page":"e41867","DOI":"10.2196\/41867","article-title":"Communicating health literacy on prescription medications on social media: in-depth interviews with \u2018patient influencers\u2019","volume":"25","author":"Willis","year":"2023","journal-title":"Journal of Medical Internet Research"},{"key":"2024121023383873000_CIT0092","first-page":"1251","article-title":"Conceptualising the commercial determinants of health using a power lens: A review and synthesis of existing frameworks","volume":"11","author":"Wood","year":"2022","journal-title":"International Journal of Health Policy and Management"},{"key":"2024121023383873000_CIT0093","author":"World Health Organisation","year":"1978"},{"key":"2024121023383873000_CIT0094","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1080\/09581596.2023.2188140","article-title":"Patient engagement in drug development: configuring a new resource for generating innovation","volume":"33","author":"Zvonareva","year":"2023","journal-title":"Critical Public Health"}],"container-title":["Health Promotion International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/heapro\/article-pdf\/39\/6\/daae188\/60999537\/daae188.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/heapro\/article-pdf\/39\/6\/daae188\/60999537\/daae188.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T23:39:16Z","timestamp":1733873956000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/heapro\/article\/doi\/10.1093\/heapro\/daae188\/7919273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,1]]},"references-count":94,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/heapro\/daae188","relation":{},"ISSN":["0957-4824","1460-2245"],"issn-type":[{"value":"0957-4824","type":"print"},{"value":"1460-2245","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,12,1]]},"article-number":"daae188"}}